0.04
+1.78%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About NDT Pharmaceuticals
Its shares trade under the ticker NDTP. It has been listed since 14 December 2006.
NDT Pharmaceuticals, Inc. is a development stage company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2006-12-14. The firm is focused on investing in Internet and mobile sectors. The firm is focused on Canadian, American and Chinese regions. The firm invests from $100,000 up-to $5Million for ownership stake in companies that require no more than $20Millionof venture capital over their life to reach cash flow positive operations, an exit, or valuation to justify growth capital as required. The Company’s portfolio includes Stockpile, OMsignal, SiVision, Klipfolio, GiaTec Scientific and rare.io.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Materials
- Industry
- Metals & Mining
- Listed since
- 14 Dec 2006
- Employees
- 1
Leadership
Pay as last reported
- Kent CarasqueroChief Executive Officer, Chief Financial Officer, Principal Accounting Officer, Director, since 2007
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- NDT Pharmaceuticals Inc has a strong portfolio of patented drugs, giving the company a competitive advantage in the market.
- The company has established partnerships with renowned research institutions, fostering innovation and access to cutting-edge technology.
- NDT Pharmaceuticals Inc has a highly skilled and experienced workforce, contributing to efficient drug development and manufacturing processes.
Weaknesses
- The company has a significant dependence on a limited number of key drugs, which poses a risk to revenue if any of those drugs face regulatory issues or patent expirations.
- NDT Pharmaceuticals Inc has a relatively small market presence compared to larger pharmaceutical corporations, making it more vulnerable to market fluctuations.
- The company lacks a diverse product pipeline, limiting its ability to enter new therapeutic areas or adapt to changing market demands.
Opportunities
- There is a growing global demand for personalized medicine, offering NDT Pharmaceuticals Inc the opportunity to develop and market targeted treatment options.
- Expansion into emerging markets, such as Asia and Latin America, presents new market opportunities for NDT Pharmaceuticals Inc to increase its customer base.
- Technological advancements in drug delivery systems create opportunities for NDT Pharmaceuticals Inc to develop innovative formulations that enhance treatment efficacy and patient convenience.
Threats
- Intense competition in the pharmaceutical industry poses a threat to NDT Pharmaceuticals Inc's market share and profitability.
- Stringent regulatory requirements and safety standards can delay the approval and launch of new drugs, affecting NDT Pharmaceuticals Inc's revenue streams.
- Pricing pressures from healthcare payers and governments may impact the company's ability to maintain profitability.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.